Portfolio company Yolk is targeting the £25bn food-to-go market. In One Basket Limited (“Yolk”), is a profitable London food-to-go-brand on a mission to “rescue busy lives from loveless food” by serving restaurant quality sandwiches, speciality coffee and better breakfast options using high-quality ingredients.
Defensible and proven model delivers highly targeted digital advertising in premium residential buildings.
Revolutionising battery materials R&D and quality control with a patented high-throughput platform that can accelerate breakthroughs by up to 10x. Developed from five years of research at the University of Cambridge, the company has achieved £500k of cumulative sales, built a £5m+ pipeline, and serves a specialist market with an estimated $7.5bn of annual battery R&D spend.
Enterprise SaaS platform streamlining complex transformation projects — from multi-million-pound drug approval programmes in pharma to large-scale IT upgrades in government. P3MO has generated £1.3m to date. At AstraZeneca, 70+ projects have reduced governance time by 72% and cut reporting effort by 90%.
Portfolio company Yolk is targeting the £25bn food-to-go market. In One Basket Limited (“Yolk”), is a profitable London food-to-go-brand on a mission to “rescue busy lives from loveless food” by serving restaurant quality sandwiches, speciality coffee and better breakfast options using high-quality ingredients.
Defensible and proven model delivers highly targeted digital advertising in premium residential buildings.
Revolutionising battery materials R&D and quality control with a patented high-throughput platform that can accelerate breakthroughs by up to 10x. Developed from five years of research at the University of Cambridge, the company has achieved £500k of cumulative sales, built a £5m+ pipeline, and serves a specialist market with an estimated $7.5bn of annual battery R&D spend.
Enterprise SaaS platform streamlining complex transformation projects — from multi-million-pound drug approval programmes in pharma to large-scale IT upgrades in government. P3MO has generated £1.3m to date. At AstraZeneca, 70+ projects have reduced governance time by 72% and cut reporting effort by 90%.
The Enterprise Investment Scheme (EIS) lets UK investors back growth companies with tax relief. Benefits include up to 30% income tax relief, plus Capital Gains, loss and Inheritance Tax advantages.
